TY - JOUR AU - Jemal, A. AU - Bray, F. AU - Center, M. M. AU - Ferlay, J. AU - Ward, E. AU - Forman, D. PY - 2011 DA - 2011// TI - Global cancer statistics JO - CA Cancer J Clin VL - 61 UR - https://doi.org/10.3322/caac.20107 DO - 10.3322/caac.20107 ID - Jemal2011 ER - TY - JOUR AU - Siegel, R. AU - Naishadham, D. AU - Jemal, A. PY - 2013 DA - 2013// TI - Cancer statistics, 2013 JO - CA Cancer J Clin VL - 63 UR - https://doi.org/10.3322/caac.21166 DO - 10.3322/caac.21166 ID - Siegel2013 ER - TY - JOUR AU - Dimitroulis, J. AU - Rapti, A. AU - Stathopoulos, G. P. AU - Rigatos, S. AU - Stathopoulos, J. AU - Koutantos, J. PY - 2008 DA - 2008// TI - Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study JO - Oncol Rep VL - 20 ID - Dimitroulis2008 ER - TY - JOUR AU - Gupta, N. AU - Hatoum, H. AU - Dy, G. K. PY - 2014 DA - 2014// TI - First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel JO - Int J Nanomedicine VL - 9 ID - Gupta2014 ER - TY - JOUR AU - Rossi, A. AU - Chiodini, P. AU - Sun, J. M. AU - O’Brien, M. E. AU - Plessen, C. AU - Barata, F. PY - 2014 DA - 2014// TI - Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70402-4 DO - 10.1016/S1470-2045(14)70402-4 ID - Rossi2014 ER - TY - JOUR AU - Liew, M. S. AU - Sia, J. AU - Starmans, M. H. AU - Tafreshi, A. AU - Harris, S. AU - Feigen, M. PY - 2013 DA - 2013// TI - Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer JO - Cancer Med VL - 2 UR - https://doi.org/10.1002/cam4.142 DO - 10.1002/cam4.142 ID - Liew2013 ER - TY - JOUR AU - Spiro, S. G. AU - Silvestri, G. A. PY - 2005 DA - 2005// TI - One hundred years of lung cancer JO - Am J Respir Crit Care Med VL - 172 UR - https://doi.org/10.1164/rccm.200504-531OE DO - 10.1164/rccm.200504-531OE ID - Spiro2005 ER - TY - JOUR AU - Kobayashi, M. AU - Fitz, L. AU - Ryan, M. AU - Hewick, R. M. AU - Clark, S. C. AU - Chan, S. PY - 1989 DA - 1989// TI - Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes JO - J Exp Med VL - 170 UR - https://doi.org/10.1084/jem.170.3.827 DO - 10.1084/jem.170.3.827 ID - Kobayashi1989 ER - TY - JOUR AU - Stern, A. S. AU - Podlaski, F. J. AU - Hulmes, J. D. AU - Pan, Y. C. AU - Quinn, P. M. AU - Wolitzky, A. G. PY - 1990 DA - 1990// TI - Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells JO - Proc Natl Acad Sci U S A VL - 87 UR - https://doi.org/10.1073/pnas.87.17.6808 DO - 10.1073/pnas.87.17.6808 ID - Stern1990 ER - TY - JOUR AU - Trinchieri, G. PY - 2003 DA - 2003// TI - Interleukin-12 and the regulation of innate resistance and adaptive immunity JO - Nat Rev Immunol VL - 3 UR - https://doi.org/10.1038/nri1001 DO - 10.1038/nri1001 ID - Trinchieri2003 ER - TY - JOUR AU - Vecchio, M. AU - Bajetta, E. AU - Canova, S. AU - Lotze, M. T. AU - Wesa, A. AU - Parmiani, G. PY - 2007 DA - 2007// TI - Interleukin-12: biological properties and clinical application JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0776 DO - 10.1158/1078-0432.CCR-07-0776 ID - Vecchio2007 ER - TY - JOUR AU - Macatonia, S. E. AU - Hsieh, C. S. AU - Murphy, K. M. AU - O’Garra, A. PY - 1993 DA - 1993// TI - Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent JO - Int Immunol VL - 5 UR - https://doi.org/10.1093/intimm/5.9.1119 DO - 10.1093/intimm/5.9.1119 ID - Macatonia1993 ER - TY - JOUR AU - Germann, T. AU - Gately, M. K. AU - Schoenhaut, D. S. AU - Lohoff, M. AU - Mattner, F. AU - Fischer, S. PY - 1993 DA - 1993// TI - Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells JO - Eur J Immunol VL - 23 UR - https://doi.org/10.1002/eji.1830230805 DO - 10.1002/eji.1830230805 ID - Germann1993 ER - TY - JOUR AU - Langowski, J. L. AU - Zhang, X. AU - Wu, L. AU - Mattson, J. D. AU - Chen, T. AU - Smith, K. PY - 2006 DA - 2006// TI - IL-23 promotes tumour incidence and growth JO - Nature VL - 442 UR - https://doi.org/10.1038/nature04808 DO - 10.1038/nature04808 ID - Langowski2006 ER - TY - JOUR AU - Eisenring, M. PY - 2010 DA - 2010// TI - vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46 JO - Nat Immunol VL - 11 UR - https://doi.org/10.1038/ni.1947 DO - 10.1038/ni.1947 ID - Eisenring2010 ER - TY - JOUR AU - Le, H. N. AU - Lee, N. C. AU - Tsung, K. AU - Norton, J. A. PY - 2001 DA - 2001// TI - Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12 JO - J Immunol VL - 167 UR - https://doi.org/10.4049/jimmunol.167.12.6765 DO - 10.4049/jimmunol.167.12.6765 ID - Le2001 ER - TY - JOUR AU - Brunda, M. J. AU - Luistro, L. AU - Warrier, R. R. AU - Wright, R. B. AU - Hubbard, B. R. AU - Murphy, M. PY - 1993 DA - 1993// TI - Antitumor and antimetastatic activity of interleukin 12 against murine tumors JO - J Exp Med VL - 178 UR - https://doi.org/10.1084/jem.178.4.1223 DO - 10.1084/jem.178.4.1223 ID - Brunda1993 ER - TY - JOUR AU - Jaime-Ramirez, A. C. AU - Mundy-Bosse, B. L. AU - Kondadasula, S. AU - Jones, N. B. AU - Roda, J. M. AU - Mani, A. PY - 2011 DA - 2011// TI - IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production JO - J Immunol VL - 186 UR - https://doi.org/10.4049/jimmunol.1000328 DO - 10.4049/jimmunol.1000328 ID - Jaime-Ramirez2011 ER - TY - JOUR AU - Ansell, S. M. AU - Witzig, T. E. AU - Kurtin, P. J. AU - Sloan, J. A. AU - Jelinek, D. F. AU - Howell, K. G. PY - 2002 DA - 2002// TI - Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma JO - Blood VL - 99 UR - https://doi.org/10.1182/blood.V99.1.67 DO - 10.1182/blood.V99.1.67 ID - Ansell2002 ER - TY - JOUR AU - Little, R. F. AU - Aleman, K. AU - Kumar, P. AU - Wyvill, K. M. AU - Pluda, J. M. AU - Read-Connole, E. PY - 2007 DA - 2007// TI - Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-06-097568 DO - 10.1182/blood-2007-06-097568 ID - Little2007 ER - TY - JOUR AU - Ardolino, M. AU - Azimi, C. S. AU - Iannello, A. AU - Trevino, T. N. AU - Horan, L. AU - Zhang, L. PY - 2014 DA - 2014// TI - Cytokine therapy reverses NK cell anergy in MHC-deficient tumors JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI74337 DO - 10.1172/JCI74337 ID - Ardolino2014 ER - TY - JOUR AU - Zitvogel, L. AU - Kroemer, G. PY - 2014 DA - 2014// TI - Cytokines reinstate NK cell-mediated cancer immunosurveillance JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI78531 DO - 10.1172/JCI78531 ID - Zitvogel2014 ER - TY - JOUR AU - Zhang, D. AU - Yang, R. AU - Wang, S. AU - Dong, Z. PY - 2014 DA - 2014// TI - Paclitaxel: new uses for an old drug JO - Drug Des Devel Ther VL - 8 ID - Zhang2014 ER - TY - JOUR AU - Dasari, S. AU - Tchounwou, P. B. PY - 2014 DA - 2014// TI - Cisplatin in cancer therapy: molecular mechanisms of action JO - Eur J Pharmacol VL - 740 UR - https://doi.org/10.1016/j.ejphar.2014.07.025 DO - 10.1016/j.ejphar.2014.07.025 ID - Dasari2014 ER - TY - JOUR AU - Wang, Z. PY - 2014 DA - 2014// TI - Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies JO - Int J Clin Exp Med VL - 7 ID - Wang2014 ER - TY - JOUR AU - Hanna, N. AU - Shepherd, F. A. AU - Fossella, F. V. AU - Pereira, J. R. AU - Marinis, F. AU - Pawel, J. PY - 2004 DA - 2004// TI - Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.08.163 DO - 10.1200/JCO.2004.08.163 ID - Hanna2004 ER - TY - JOUR AU - Rupaimoole, R. AU - Wu, S. Y. AU - Pradeep, S. AU - Ivan, C. AU - Pecot, C. V. AU - Gharpure, K. M. PY - 2014 DA - 2014// TI - Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression JO - Nat Commun VL - 5 UR - https://doi.org/10.1038/ncomms6202 DO - 10.1038/ncomms6202 ID - Rupaimoole2014 ER - TY - JOUR AU - Joshi, H. P. AU - Subramanian, I. V. AU - Schnettler, E. K. AU - Ghosh, G. AU - Rupaimoole, R. AU - Evans, C. PY - 2014 DA - 2014// TI - Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1317242111 DO - 10.1073/pnas.1317242111 ID - Joshi2014 ER - TY - JOUR AU - Cao, X. AU - Leonard, K. AU - Collins, L. I. AU - Cai, S. F. AU - Mayer, J. C. AU - Payton, J. E. PY - 2009 DA - 2009// TI - Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-09-1145 DO - 10.1158/0008-5472.CAN-09-1145 ID - Cao2009 ER - TY - JOUR AU - Kilinc, M. O. AU - Aulakh, K. S. AU - Nair, R. E. AU - Jones, S. A. AU - Alard, P. AU - Kosiewicz, M. M. PY - 2006 DA - 2006// TI - Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors JO - J Immunol VL - 177 UR - https://doi.org/10.4049/jimmunol.177.10.6962 DO - 10.4049/jimmunol.177.10.6962 ID - Kilinc2006 ER - TY - JOUR AU - Tsung, K. AU - Meko, J. B. AU - Tsung, Y. L. AU - Peplinski, G. R. AU - Norton, J. A. PY - 1998 DA - 1998// TI - Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12 JO - J Immunol VL - 160 ID - Tsung1998 ER - TY - JOUR AU - Dowlati, A. AU - Crosby, L. AU - Remick, S. C. AU - Makkar, V. AU - Levitan, N. PY - 2001 DA - 2001// TI - Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials JO - Lung Cancer VL - 32 UR - https://doi.org/10.1016/S0169-5002(00)00220-8 DO - 10.1016/S0169-5002(00)00220-8 ID - Dowlati2001 ER - TY - JOUR AU - Yu, H. K. AU - Lee, H. J. AU - Yun, S. J. AU - Lee, S. J. AU - Langley, R. R. AU - Yoon, Y. PY - 2014 DA - 2014// TI - Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model JO - Transl Oncol VL - 7 UR - https://doi.org/10.1016/j.tranon.2014.04.005 DO - 10.1016/j.tranon.2014.04.005 ID - Yu2014 ER - TY - JOUR AU - Lengyel, E. AU - Litchfield, L. M. AU - Mitra, A. K. AU - Nieman, K. M. AU - Mukherjee, A. AU - Zhang, Y. PY - 2014 DA - 2014// TI - Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models JO - Am J Obstet Gynecol ID - Lengyel2014 ER - TY - JOUR AU - Kao, C. J. AU - Wurz, G. T. AU - Monjazeb, A. M. AU - Vang, D. P. AU - Cadman, T. B. AU - Griffey, S. M. PY - 2014 DA - 2014// TI - Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0205 DO - 10.1158/2326-6066.CIR-13-0205 ID - Kao2014 ER - TY - JOUR AU - Bracci, L. AU - Schiavoni, G. AU - Sistigu, A. AU - Belardelli, F. PY - 2014 DA - 2014// TI - Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer JO - Cell Death Differ VL - 21 UR - https://doi.org/10.1038/cdd.2013.67 DO - 10.1038/cdd.2013.67 ID - Bracci2014 ER - TY - JOUR AU - Ramakrishnan, R. AU - Gabrilovich, D. I. PY - 2013 DA - 2013// TI - Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer JO - Cancer Immunol Immunother VL - 62 UR - https://doi.org/10.1007/s00262-012-1390-6 DO - 10.1007/s00262-012-1390-6 ID - Ramakrishnan2013 ER - TY - JOUR AU - Javeed, A. AU - Ashraf, M. AU - Riaz, A. AU - Ghafoor, A. AU - Afzal, S. AU - Mukhtar, M. M. PY - 2009 DA - 2009// TI - Paclitaxel and immune system JO - Eur J Pharm Sci VL - 38 UR - https://doi.org/10.1016/j.ejps.2009.08.009 DO - 10.1016/j.ejps.2009.08.009 ID - Javeed2009 ER - TY - JOUR AU - Markasz, L. AU - Stuber, G. AU - Vanherberghen, B. AU - Flaberg, E. AU - Olah, E. AU - Carbone, E. PY - 2007 DA - 2007// TI - Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-06-0358 DO - 10.1158/1535-7163.MCT-06-0358 ID - Markasz2007 ER - TY - JOUR AU - Nastala, C. L. AU - Edington, H. D. AU - McKinney, T. G. AU - Tahara, H. AU - Nalesnik, M. A. AU - Brunda, M. J. PY - 1994 DA - 1994// TI - Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production JO - J Immunol VL - 153 ID - Nastala1994 ER - TY - JOUR AU - Smyth, M. J. AU - Taniguchi, M. AU - Street, S. E. PY - 2000 DA - 2000// TI - The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent JO - J Immunol VL - 165 UR - https://doi.org/10.4049/jimmunol.165.5.2665 DO - 10.4049/jimmunol.165.5.2665 ID - Smyth2000 ER - TY - JOUR AU - Segal, J. G. AU - Lee, N. C. AU - Tsung, Y. L. AU - Norton, J. A. AU - Tsung, K. PY - 2002 DA - 2002// TI - The role of IFN-gamma in rejection of established tumors by IL-12: source of production and target JO - Cancer Res VL - 62 ID - Segal2002 ER - TY - JOUR AU - Komita, H. AU - Homma, S. AU - Saotome, H. AU - Zeniya, M. AU - Ohno, T. AU - Toda, G. PY - 2006 DA - 2006// TI - Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8 + T cells directly induces apoptosis of mouse hepatocellular carcinoma JO - J Hepatol VL - 45 UR - https://doi.org/10.1016/j.jhep.2006.05.018 DO - 10.1016/j.jhep.2006.05.018 ID - Komita2006 ER - TY - JOUR AU - Coughlin, C. M. AU - Salhany, K. E. AU - Gee, M. S. AU - LaTemple, D. C. AU - Kotenko, S. AU - Ma, X. PY - 1998 DA - 1998// TI - Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis JO - Immunity VL - 9 UR - https://doi.org/10.1016/S1074-7613(00)80585-3 DO - 10.1016/S1074-7613(00)80585-3 ID - Coughlin1998 ER - TY - JOUR AU - Paavonen, K. AU - Puolakkainen, P. AU - Jussila, L. AU - Jahkola, T. AU - Alitalo, K. PY - 2000 DA - 2000// TI - Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing JO - Am J Pathol VL - 156 UR - https://doi.org/10.1016/S0002-9440(10)65021-3 DO - 10.1016/S0002-9440(10)65021-3 ID - Paavonen2000 ER - TY - JOUR AU - Clarijs, R. AU - Schalkwijk, L. AU - Hofmann, U. B. AU - Ruiter, D. J. AU - Waal, R. M. PY - 2002 DA - 2002// TI - Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma JO - Cancer Res VL - 62 ID - Clarijs2002 ER - TY - JOUR AU - Sgadari, C. AU - Angiolillo, A. L. AU - Tosato, G. PY - 1996 DA - 1996// TI - Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10 JO - Blood VL - 87 ID - Sgadari1996 ER - TY - JOUR AU - Kanegane, C. AU - Sgadari, C. AU - Kanegane, H. AU - Teruya-Feldstein, J. AU - Yao, L. AU - Gupta, G. PY - 1998 DA - 1998// TI - Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12 JO - J Leukoc Biol VL - 64 ID - Kanegane1998 ER - TY - JOUR AU - Mitola, S. AU - Strasly, M. AU - Prato, M. AU - Ghia, P. AU - Bussolino, F. PY - 2003 DA - 2003// TI - IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production JO - J Immunol VL - 171 UR - https://doi.org/10.4049/jimmunol.171.7.3725 DO - 10.4049/jimmunol.171.7.3725 ID - Mitola2003 ER - TY - JOUR AU - Leonard, J. P. AU - Sherman, M. L. AU - Fisher, G. L. AU - Buchanan, L. J. AU - Larsen, G. AU - Atkins, M. B. PY - 1997 DA - 1997// TI - Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production JO - Blood VL - 90 ID - Leonard1997 ER - TY - JOUR AU - Cohen, J. PY - 1995 DA - 1995// TI - IL-12 deaths: explanation and a puzzle JO - Science VL - 270 UR - https://doi.org/10.1126/science.270.5238.908a DO - 10.1126/science.270.5238.908a ID - Cohen1995 ER - TY - JOUR AU - Sacco, S. AU - Heremans, H. AU - Echtenacher, B. AU - Buurman, W. A. AU - Amraoui, Z. AU - Goldman, M. PY - 1997 DA - 1997// TI - Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids JO - Blood VL - 90 ID - Sacco1997 ER - TY - JOUR AU - Bajetta, E. AU - Vecchio, M. AU - Mortarini, R. AU - Nadeau, R. AU - Rakhit, A. AU - Rimassa, L. PY - 1998 DA - 1998// TI - Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma JO - Clin Cancer Res VL - 4 ID - Bajetta1998 ER - TY - JOUR AU - Motzer, R. J. AU - Rakhit, A. AU - Schwartz, L. H. AU - Olencki, T. AU - Malone, T. M. AU - Sandstrom, K. PY - 1998 DA - 1998// TI - Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma JO - Clin Cancer Res VL - 4 ID - Motzer1998 ER - TY - JOUR AU - Bekaii-Saab, T. S. AU - Roda, J. M. AU - Guenterberg, K. D. AU - Ramaswamy, B. AU - Young, D. C. AU - Ferketich, A. K. PY - 2009 DA - 2009// TI - A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies JO - Mol Cancer Ther VL - 8 UR - https://doi.org/10.1158/1535-7163.MCT-09-0820 DO - 10.1158/1535-7163.MCT-09-0820 ID - Bekaii-Saab2009 ER -